DUPIXENT reduced polyp burden as early as Week 4 (LSM difference vs placebo: -1.15 [95% CI: -1.40, -0.91]) in SINUS-52.⁶

In the same study, patients saw a significant reduction in the size of nasal polyps, as measured by NPS:

• -1.71 improvement in NPS at Week 24 with DUPIXENT 300 mg Q2W + INCS (n=295, pooled DUPIXENT arms) (baseline score 6.18) vs 0.10 worsening with placebo + INCS (n=153) (baseline score 5.96) (LSM difference vs placebo: -1.80 [95% CI: -2.10, -1.51]) (coprimary endpoint)¹
• -2.24 improvement in NPS at Week 52 with DUPIXENT 300 mg Q2W + INCS (n=150) (baseline score 6.07) vs 0.15 worsening with placebo + INCS (n=153) (baseline score 5.96) (LSM difference vs placebo: -2.40 [95% CI: -2.77, -2.02]) (key secondary endpoint)⁷

Nasal polyp score (NPS) is the sum of right and left nostril scores (range 0 to 8) as evaluated by nasal endoscopy: reduced score indicates improvement.

INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.

See what polyp reduction looks like with DUPIXENT